Genuv partners with Aiforia for AI-Powered Drug Screening Platform
pharmafile | February 15, 2022 | News story | Manufacturing and Production |
Genuv has announced an agreement with the medical technology company Aiforia Technologies, to add Aiforia’s AI deep learning for medical image analysis to its ATRIVIEW® discovery platform.
ATRIVIEW is Genuv’s proprietary drug discovery platform. The ATRIVIEW AI platform enables faster and more consistent screening of molecules that demonstrate neuroprotective and neurogenerative effects. The platform will incorporate Aiforia’s deep learning artificial intelligence technology and will enable faster drug discovery and simultaneous analysis of multiple biomarkers. It is used to screen both existing drugs and new substances for neuroprotective and neurogenerative effects.
“Aiforia is helping Genuv bring the power of deep learning artificial intelligence to our unique ATRIVIEW drug discovery platform,” said Sungho Han, PhD, founder and CEO of Genuv. “The additional speed will enable Genuv and our partners to bring more drug candidates to the clinic more quickly.”
Genuv is a clinical-stage biotechnology company, focused on innovative drug discovery for central nervous system disorders, and developing advanced antibody therapies. The company’s lead drug candidate, SNR1611, was discovered with ATRIVIEW. SNR1611 has been shown to restore CNS functions in preclinical models of amyotrophic lateral sclerosis (ALS) and Alzheimer’s Disease. It is now being studied in a PhaseI/IIa clinical trial for ALS.
“We’re excited to help Genuv extend the capabilities of the remarkable ATRIVIEW platform with the help of our powerful, deep learning technology,” said Jukka Tapaninen, CEO of Aiforia Technologies Plc. “Aiforia brings increased efficiency and precision to medical image analysis in fields including neuroscience. ATRIVIEW is a powerful approach to the enormous unmet need in neurodegenerative diseases and we are humbled to be a part of this collaboration.”
Aiforia’s image analysis tools are used by many major pharmaceutical and biotechnology firms, including Sanofi, Boehringer Ingelheim, AstraZeneca and Bristol Myers Squibb. The partnership with Genuv marks the first time Aiforia’s technology is being used in neuroscience drug discovery for neurodegenerative diseases such as ALS and Alzheimer’s disease.